# Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes

> **NCT07392125** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Achieve Life Sciences** · enrollment: 800 (estimated)

## Conditions studied

- Vaping Cessation

## Interventions

- **DRUG:** Cytisinicline
- **DRUG:** Placebo
- **BEHAVIORAL:** Behavioral Support

## Key facts

- **NCT ID:** NCT07392125
- **Lead sponsor:** Achieve Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2026-11-15
- **Final completion:** 2027-09-30
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392125, "Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07392125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*